Cargando…
Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
KEY POINTS: The contribution of IV methylprednisolone to glucocorticoid toxicity is often overlooked with limited evidence supporting its use. Markedly reduced cumulative glucocorticoid dosing for remission induction therapy in AAV is safe and effective. Reduced IV methylprednisolone and radical ste...
Autores principales: | Floyd, Lauren, Morris, Adam D., Shetty, Anamay, Brady, Mark E., Ponnusamy, Arvind, Warwicker, Paul, Dhaygude, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Nephrology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547218/ https://www.ncbi.nlm.nih.gov/pubmed/37668468 http://dx.doi.org/10.34067/KID.0000000000000222 |
Ejemplares similares
-
Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?
por: Floyd, Lauren, et al.
Publicado: (2022) -
Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
por: Chanouzas, Dimitrios, et al.
Publicado: (2019) -
The impact of COVID-19 pandemic on patients with ANCA associated vasculitis
por: Kant, Sam, et al.
Publicado: (2020) -
Intravenous Methylprednisolone in Induction Therapy for ANCA-Associated Vasculitis: How Low Can We Go?
por: Oliva-Damaso, Nestor, et al.
Publicado: (2023) -
Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
por: Wang, Choon Ying, et al.
Publicado: (2022)